-
Mashup Score: 1
Objective We present the final analysis results of the phase 2 JADE study (ClinicalTrials.gov Identifier: [NCT03361956][1]). Design 232 patients with chronic hepatitis B (CHB) not currently treated at study start (NCT) at study start or virologically suppressed were randomised to receive 75 mg (part 1) or 250 mg (part 2) JNJ-56136379, a hepatitis B virus (HBV)–capsid assembly modulator, one time…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0
Objective We present the final analysis results of the phase 2 JADE study (ClinicalTrials.gov Identifier: [NCT03361956][1]). Design 232 patients with chronic hepatitis B (CHB) not currently treated at study start (NCT) at study start or virologically suppressed were randomised to receive 75 mg (part 1) or 250 mg (part 2) JNJ-56136379, a hepatitis B virus (HBV)–capsid assembly modulator, one time…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper by Janssen et al entitled "Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection" via https://t.co/B4eQxnjfQ7 #HBV #LiverTwitter https://t.co/edwkPJR0Cd
-
-
Mashup Score: 0
Objective We present the final analysis results of the phase 2 JADE study (ClinicalTrials.gov Identifier: [NCT03361956][1]). Design 232 patients with chronic hepatitis B (CHB) not currently treated at study start (NCT) at study start or virologically suppressed were randomised to receive 75 mg (part 1) or 250 mg (part 2) JNJ-56136379, a hepatitis B virus (HBV)–capsid assembly modulator, one time…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper by Janssen et al entitled "Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection" via https://t.co/B4eQxnjfQ7 #HBV #LiverTwitter https://t.co/YigqhMSaK1
-
-
Mashup Score: 0
Chronic hepatitis B virus infection was significantly associated with an increased risk for intracerebral hemorrhage but not other types of stroke in Chinese adults, according to data presented at the EASL Congress. “China has the greatest burden of hepatitis B in the world,” Elizabeth Hamilton, a DPhil candidate in the Nuffield Department of Population Health at the University
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
Chronic #HBV infection linked to increased risk for #intracerebralhemorrhage #EASLCongress #LiverTwitter @EASLnews https://t.co/zpeBEsUdNn
-
-
Mashup Score: 0Global Vaccine Alliance to deploy six-in-one vaccine to lower-income countries, establish innovative mechanisms to protect against future epidemic threats - 10 month(s) ago
Gavi’s Board approved new investments in six-in-one (hexavalent) vaccine and approved a long list of potential new vaccines for consideration for inclusion in future Gavi programmes at its Board Meeting, which concluded today
Source: www.gavi.orgCategories: Gastroenterology, Latest HeadlinesTweet-
Gavi to restart programmes for vaccines approved but paused (eg, due to the pandemic), including the #HepB birth dose vaccine. Timelines, technical guidance, and parameters of the new programmes to follow… #NoHep #LiverTwitter #IDTwitter @Gavi #HBV https://t.co/XzgNDXGQ27
-
-
Mashup Score: 0Older age, high HBsAg levels linked to increased risk for flare after treatment withdrawal - 10 month(s) ago
Older age, male sex and increased hepatitis B surface antigen correlated with a higher risk for hepatic flare after nucleos(t)ide analogue withdrawal in patients with chronic HBV, according to data at the EASL Congress. “Over the last decades, several studies have shown that stopping new treatment in a selective group of patients may be beneficial since this could result in functional cure,
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
@DrLoomba Older #age, #malesex and increased #hepatitisB surface antigen correlated with a higher risk for #hepaticflare after nucleos(t)ide analogue withdrawal in patients with chronic #HBV, according to data at the #EASLCongress. https://t.co/2ATod3Tvkt
-
-
Mashup Score: 0
Objective We present the final analysis results of the phase 2 JADE study (ClinicalTrials.gov Identifier: [NCT03361956][1]). Design 232 patients with chronic hepatitis B (CHB) not currently treated at study start (NCT) at study start or virologically suppressed were randomised to receive 75 mg (part 1) or 250 mg (part 2) JNJ-56136379, a hepatitis B virus (HBV)–capsid assembly modulator, one time…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper by Janssen et al entitled "Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection" via https://t.co/B4eQxnjfQ7 #HBV #LiverTwitter https://t.co/642aeUH3rk
-
-
Mashup Score: 0Older age, high HBsAg levels linked to increased risk for flare after treatment withdrawal - 11 month(s) ago
Older age, male sex and increased hepatitis B surface antigen correlated with a higher risk for hepatic flare after nucleos(t)ide analogue withdrawal in patients with chronic HBV, according to data at the EASL Congress. “Over the last decades, several studies have shown that stopping new treatment in a selective group of patients may be beneficial since this could result in functional cure,
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
@MadrigalPharma @mirumpharma Older #age, #male #sex and increased #hepatitisB surface antigen correlated with a higher risk for hepatic flare after nucleos(t)ide analogue withdrawal in patients with chronic #HBV, according to data at the #EASLCongress. https://t.co/2ATod3Tvkt
-
-
Mashup Score: 0Older age, high HBsAg levels linked to increased risk for flare after treatment withdrawal - 11 month(s) ago
Older age, male sex and increased hepatitis B surface antigen correlated with a higher risk for hepatic flare after nucleos(t)ide analogue withdrawal in patients with chronic HBV, according to data at the EASL Congress. “Over the last decades, several studies have shown that stopping new treatment in a selective group of patients may be beneficial since this could result in functional cure,
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#Olderage, #malesex and increased #hepatitisBsurfaceantigen correlated with a higher risk for #hepaticflare after nucleos(t)ide analogue withdrawal in #patients with chronic #HBV, Edo Dongelmans, MD of @erasmusuni, said at #EASLCongress https://t.co/QUdMwqAh4f
-
-
Mashup Score: 0Racial Disparities in Chronic Hepatitis B: Implications for Treatment and Outcomes - 11 month(s) ago
While African American/Black participants were less likely to meet treatment criteria, treatment receipt did not significantly differ by race, indicating equitable access to treatment.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet-
This observational study of chronic hepatitis B (#HBV) found African American/Black participants were less likely than other races to meet the criteria necessary to initiate HBV treatment. #HealthEquity #Juneteenth https://t.co/OCjNqg0Fke
-
#GUTImage from the paper by Janssen et al entitled "Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection" via https://t.co/B4eQxnjfQ7 #HBV #LiverTwitter https://t.co/uI79qrVUto